| 1. | Report of the Medical Research Council Working Party. Long term domiciliary oxygen therapy in chronic hypoxic cor pulmonale complicating chronic bronchitis and emphysema. Lancet 1981;1:681–686. |
| 2. | Kvale PA, Cugell DW, Anthonisen NR, et al., for the Nocturnal Oxygen Therapy Trial Group. Continuous or nocturnal oxygen therapy in hypoxemic chronic obstructive lung disease. Ann Intern Med 1980;93:391–398. |
| 3. | Guyatt GH, McKim DA, Austin P, Bryan R, Norgren J, Weaver B, Bédard M, Goldstein RS. Appropriateness of domiciliary oxygen delivery. Chest 2000;118:1303–1308. |
| 4. | Guyatt GH, McKim DA. Weaver B, Austin P, Bryan REJ, Walter SD, Nonoyama ML, Ferreira IM, Goldstein RS. Development and testing of formal protocols for oxygen prescribing. Am J Respir Crit Care Med 2001;163:942–946. |
| 5. | Young IH, Crockett AJ, McDonald CF. Adult domiciliary oxygen therapy: position statement of the Thoracic Society of Australia and New Zealand. N Z Med J 1999;112:15–18. |
| 6. | Petty T, Casaburi R. Recommendations of the Fifth Oxygen Consensus Conference. Writing and Organizing Committees. Respir Care 2000;45:957–961. |
| 7. | Wedzicha J. Domiciliary oxygen therapy services: clinical guidelines and advice for prescribers. Summary of a report of the Royal College of Physicians. J R Coll Physicians Lond 1999;33:445–447. |
| 8. | Department of Health and Home Services. Center for Medicare and Medicaid Services; Transmittal 1742; March 2002 [cited December 1, 2004]. Available from http://www.cms.hhs.gov/manuals/pm_trans/R1742B3.pdf. |
| 9. | Celli BR, MacNee W. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur Respir J 2004;23:932–946. |
| 10. | Oba Y, Salzman GA, Willsie SK. Re-evaluation of continuous oxygen therapy after initial prescription in patients with chronic obstructive pulmonary disease. Respir Care 2000;45:401–406. |
| 11. | Chaney JC, Jones K, Grathwohl K, Olivier KN. Implementation of an oxygen therapy clinic to manage users of long-term oxygen therapy. Chest 2002;122:1661–1667. |
| 12. | National Heritage Insurance Company (NHIC). Medicare Participating Provider Program Fee Disclosure, 2004 Revised Fee Schedule, Area 26, NHIC, Centers for Medicare and Medicaid Services Publication. Available from http://medicarenhic.com/cal_prov/fees/archives/2004revfee_area26.pdf. |
| 13. | Guyatt GH, Berman LB, Townsend M, Pugsley SO, Chambers LW. A measure of quality of life for clinical trials in chronic lung disease. Thorax 1987;42:773–778. |
| 14. | Lacasse Y, Wong E, Guyatt GH, Goldstein RS. Health-status measurement instruments in chronic obstructive pulmonary disease. Can Respir J 1997;4:152–164. |
| 15. | DerSimonian R, Laird N. Meta analysis in clinical trials. Control Clin Trials 1986;7:177–188. |
| 16. | Jaeschke R, Singer J, Guyatt GH. Measurement of health status: ascertaining the minimal clinically important difference. Control Clin Trials 1989;10:407–415. |
| 17. | Seemungal TA, Donaldson GC, Paul EA, Bestall JC, Jeffries DJ, Wedzicha JA. Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1998;157:1418–1422. |
| 18. | Seemungal TA, Donaldson GC, Bhowmik A, Jeffries DJ, Wedzicha JA. Time course and recovery of exacerbations in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2000;161:1608–1613. |
| 19. | Spencer S, Jones PW. Time course of recovery of health status following an infective exacerbation of chronic bronchitis. Thorax 2003;58:589–593. |
